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ABSTRACT
Background: Individuals with depression have a higher incidence of comorbidity which
significantly decreases their ability to function and increases their utilization of health care. Due
to the severity of the economic burden resulting with depression, research is needed to further
examine the most effective treatments for depression. Biofeedback is a therapy that teaches
patients how to control the physical affects that manifest during depression.
Aim: The purpose of this review of literature is to discover the benefits of biofeedback for
patients diagnosed with depression.
Method: An electronic literature search was conducted using various databases to retrieve
articles examining biofeedback as an intervention for patients with depression or depressive
symptoms.
Results: Studies that used biofeedback as an intervention for depression reported significant
physical benefits for patients, including decreased heart rate variability and respiratory rate, as
well as improved function.
Conclusion: Research indicates that treatments need to have the potential to empower
individuals, relieve them of their negative symptoms, relieve their financial burden, and allow
them the quality of life they deserve.
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INTRODUCTION
Depression is one of the leading causes of disability in the United States and affects a
staggering 350 million people worldwide (World Health Organization [WHO], 2016). The
impact of depression is not only concerning because of the amount of people who suffer with
sadness, hopelessness, and physical symptoms, but it is troubling because, out of those 350
million people, many of them will attempt suicide. In 2013, the Centers for Disease Control and
Prevention (CDC) revealed that 41,149 people died in the United States as a result of suicide
(CDC, 2016).
Depression negatively impacts the quality of life and is often accompanied by other chronic
illnesses (CDC, 2014). Patients with depression have a higher incidence of comorbidity, which
significantly decreases their ability to function and, in turn, increases their health care utilization
(CDC, 2014). Common mental health comorbidities occurring with depression include panic
disorder, substance-related disorders, obsessive-compulsive disorder, anorexia nervosa, bulimia
nervosa, and borderline personality disorder (APA, 2013). In addition, depression may
complicate other comorbid conditions, such as heart disease, chronic obstructive pulmonary
disease, inflammatory bowel disease, diabetes, and cancer (Katon, 2003).
Decreased work performance is associated with the increased health care needs resulting
with depression (Wang, Simon, & Kessler, 2003). Fatigue, anergia, difficulty concentrating,
impaired decision making, and social isolation resulting from depression significantly decreases
work productivity (NIMH, 2015; Wang, Simon, & Kessler, 2003). Individuals with depression
require considerably more disability days than those individuals who are not depressed, placing
significant economic burden on both the individual and the economy as a whole (Greenburg,
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Fournier, Sisitsky, Pike, & Kessler, 2015). In 2010, the economic burden placed on individuals
with depression was an estimated $102 million dollars of workplace costs (Greenburg et. al,
2015). Due to the severity of the economic burden resulting with depression, research is needed
to further examine the most effective treatments for depression.

2

PROBLEM
Current therapies that teach patients how to self-regulate symptoms of depression through
cognitive strategies focus on mental awareness to promote effective coping (Beal, 2014).
Biofeedback teaches patients to focus their attention on the biological manifestations of
depression, such as decreased Heart Rate Variability (HRV), increased respiration rate, and slow
cortical potentials (Karavidas et al., 2007). When combined with alternative therapies, such as
group sessions, meditation, and physical activity, biofeedback has the potential to holistically
benefit patients learning to effectively cope with depression. Cost-effective treatments that
empower individuals and provide symptom relief will promote their quality of life. A review of
the literature will promote understanding of the possible benefits of biofeedback for patients
diagnosed with depression.

3

PURPOSE
The purpose of this review of literature is to discover the benefits of biofeedback for
patients diagnosed with MDD. Further understanding is needed concerning the use and efficacy
of biofeedback therapy for clients with MDD. Literature was reviewed concerning how
biofeedback is used to treat the symptoms experienced by patients with MDD, the benefits of
effective coping, and to provide recommendations for further research.
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METHOD
An electronic search was conducted to retrieve research articles on the use of biofeedback
to help patients effectively cope with depressive symptoms. Databases used to locate research
articles included CINAHL Plus with Full Text, Cochrane Central Register of Controlled Trials,
Cochrane Database of Systematic Reviews, MEDLINE, PsycARTICLES, and PsycINFO. Key
terms were broken up into three search bars in the order of, (MH "Depression") OR Depress*, in
the first search bar, AB biofeedback OR TI Biofeedback, in the second search bar, and (MH
"Coping") OR Coping OR cope OR stress manag* OR anxiety manag*, in the third search bar.
Each of these searches were separated by, “AND,” in order to find each detailed search within
the articles. Inclusion criteria for an article included research that focused on biofeedback as an
independent variable and the outcomes of coping, stress, and/or depressive symptoms, including
anergia, anhedonia, and social isolation. Articles were excluded if the progression of depression
symptoms was not analyzed. The only limiter placed on the initial search was “English
language” in order to obtain more articles. The first search brought up 170 articles. Then after
examining the titles for inclusion, there were 27 articles. After the abstract review looking
further into the criteria, 11 articles were left. Then, after examining the complete articles, eight
studies were left that matched the inclusion criteria for what this review sought to discover.
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BACKGROUND
Depression
Depression may manifest in multiple forms. The Diagnostic and Statistical Manual of
Mental Disorders (DSM-V) classifies depressive disorders based on the individual’s clinical
presentation. Depressive disorders may include Major Depressive Disorder (MDD), Persistent
Depressive Disorder (dysthymia), Disruptive Mood Dysregulation Disorder, and unspecified
depressive disorder (American Psychiatric Association [APA], 2013). Criteria used to determine
the appropriate psychiatric diagnosis differ in relation to time, duration, and presumed etiology
(APA, 2013). Traits, or specifiers, that differentiate depression further include anxious distress;
mixed features; melancholic features; atypical features; mood-congruent psychotic features;
mood-incongruent psychotic features; peripartum onset; catatonia, and seasonal patterns (APA,
2013). Following accurate diagnosis, treatment will be determined based on that individuals’
healthcare situation and needs. These treatments usually consist of medication, psychotherapies,
and electroconvulsive therapy (ECT).
Major Depressive Disorder
Major Depressive Disorder is one of the most common mental disorders in the United States,
but its effects extend beyond psychological symptoms (National Institute of Mental Health,
2016). Disorders involving depression can be severely debilitating for memory, attention span,
role functioning, and it can increase fatigue during tasks that used to be easy (APA, 2013;
Centers for Disease Control and Prevention [CDC], 2014). As a result of such debilitating
symptoms, the healthcare impact is considerable. The financial burden may be equally
debilitating.
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Symptoms of Major Depressive Disorder
A patient diagnosed with MDD will have displayed at least five symptoms signifying a
change in their normal functioning for two weeks or more (APA, 2013). These symptoms
include: depressed mood for much of the day, anhedonia, significant weight fluctuations,
insomnia, hypersomnia, severe energy loss, feelings of guilt, feelings of lacking worth, decreased
concentration and ability to make decisions, memory impairment, and continuous thoughts of
harming oneself (APA, 2013). The physical symptoms of anergia, memory impairment, and
decreased concentration illustrate how depression may be addressed through therapies that
address more than just a target behavior or thought. It would be beneficial to know what types of
biofeedback might also address the fatigue and decreased cognition resulting with depression.
Autonomic Nervous System
The autonomic nervous system (ANS) has also been affected by the physiological changes
resulting with depression (Kreibig, 2010). The involuntary controls regulated by the ANS can be
categorized into either the parasympathetic nervous system (PSNS) or the sympathetic nervous
system (SNS) (Olson, 2014). The PSNS creates a calming effect on the body by causing
physiological events such as slowed heart rate, increased intestinal peristalsis, increased
endocrine activity, and relaxed sphincters (Mosby, Inc., 2009). Naturally, the SNS has the
opposite effect on the body and causes an increase in heart rate, blood vessel constriction, and
increased blood pressure (Mosby, Inc., 2009).
Heart Rate Variability
Collectively the ANS has influence over cardiac muscle cells, smooth muscle cells, and
glands (Olson, 2014). More specifically, heart rate variability (HRV) has been used as a tool to
measure the adaptability of the cardiovascular system under the influence of depression
(Karavidas, 2007). When body systems regulated by the ANS showed negative changes, it was
7

evident that depression causes high sympathetic arousal to the point where stressors can no
longer be addressed through a sympathetic response (Karavidas, 2007). Therefore, increased
heart rate and decreased HRV for people with depression is associated with a prolonged increase
in SNS activation (Kreibig, 2010; Vasudev, Cha, & McIntyre, 2015).

Therapeutic Interventions
Clinical practice guidelines developed by the National Institute for Health and Care
Excellence [NICE] (2009), the Institute for Clinical Systems Improvement (2016), and the
American Psychological Association (2010) address the healthcare needs of clients with
depression. These treatments may consist of pharmacotherapy, variations of cognitive behavioral
therapy, and structured group programs (NICE, 2009). Although these recommended
interventions provide many benefits for patients, guidelines still fail to acknowledge biofeedback
therapies as treatment options to help patients control the possible physical manifestations of
depression.
Cognitive Behavioral Therapy
Cognitive Behavioral Therapy (CBT), when combined with supplemental treatment, has
the potential to enhance coping in depression (Parikh et al, 2016). CBT is a therapy commonly
used in the treatment of depression. CBT teaches patients how to recognize negative thought
processes and how to incorporate better strategies for effective coping and stress management
(National Association of Cognitive-Behavioral Therapists [NACBT], 2016). Parikh et al. (2016)
found that CBT that was paired with antidepressants decreased the likelihood of a depressive
relapse by 20%. This finding should be researched further to discover whether or not CBT
would also be enhanced by the addition of biofeedback therapy.
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Neurofeedback
The effects of neurofeedback, a version of biofeedback therapy, for patients with MDD were
examined by Cheon, Koo, and Choi (2016). Neurofeedback specifically focuses on information
that is generated by the nervous system rather than information that comes from the heart, lungs,
muscles, or temperature; which is referred to as biofeedback. This prospective, open-label study
was conducted to examine the effects of left prefrontal beta with alpha/theta training on
depression. Results indicated that neurofeedback therapy was effective in improving depression
symptoms, anxiety symptoms, and clinical illness severity for study participants (Cheon et al.,
2016). Due to its positive effects for that sample, further consideration of biofeedback for clients
with a primary diagnosis dealing with depression is needed.

Biofeedback
Biofeedback is a therapy that has been primarily used for tension headaches, chronic
pain, spasmodic torticollis, temporomandibular joint dysfunction, ADHD, and epilepsy (Frank,
Khorshid, Kiffer, Morayec, & McKee, 2010). Various forms of biofeedback are used to monitor
and adjust heart rate, respirations, muscle tension, and temperature at the skin surface in order to
help control the aforementioned ailments (Frank et. al, 2010; Mackay, Buckingham, Schwartz,
Hodgkinson, Beran, & Cordato, 2015). A trained professional conducts an initial assessment
with the patient to determine their needs and individualize their plan of care. Two forms of
biofeedback commonly used include surface electromyography (sEMG) and
Electroencephalography (EEG) (Frank et. al, 2010). Surface electromyography (sEMG) is the
physiologic form of biofeedback that is most commonly used; while electroencephalography
(EEG), also known as neurofeedback, helps with disorders that are caused by and focus on the
nervous system (Frank et. al, 2010). Once an intervention is chosen, the patient is connected to a
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monitor that displays a visual representation of their physical status. This visual image shows a
change in such physiological symptoms as heart rate and respirations. The patient is then able to
work with the health care professional to learn to control their physical symptoms. Watching the
image on the screen helps the patient determine which symptoms are felt with each type of
intervention. This therapy teaches patients ways to control their body, so that one day they will
be able to self-regulate independently. Patients who are encouraged to participate in biofeedback
therapy use it as an alternative or adjunctive therapy alongside medications and other forms of
therapy (Frank et. al, 2010).
Treatment guidelines for depression presently lack sufficient research and consideration
for biofeedback therapy as an intervention for MDD. Health care providers should seek how
biofeedback therapy, as a sole or supplemental treatment option, could benefit their patients
experiencing depression. The roles of patient advocate and educator would be strengthened
through nurses’ understanding of biofeedback as a therapeutic intervention. Biofeedback therapy
complements holistic nursing care by addressing the psychological and physical needs of
patients.

Summary
All in all, this literature review is important for discerning whether or not everything is
being considered when it comes to treating patients with depression. Due to the nature of
depression’s effect on ability to work, exercise tolerance, memory, creating reliance on long term
therapies, and more, further research is needed to investigate multiple treatment options that
could address some of the symptoms more appropriately.

10

RESULTS
The majority of studies retrieved with this review of the literature were experimental
designs, including two quasi experimental studies (Staples, Abdel Atti, & Gordon, 2011; Tan et
al., 2013) and four randomized controlled trials (Swanson et al., 2009; Climov et al., 2014;
Kotozaki et al., 2014; Zwan, Vente, Huizink, Bögels, & Bruin, 2015). The remaining studies
were a cross-sectional study (Nahshoni et al., 2004) and a systematic review (Canadian Agency
for Drugs and Technologies in Health, 2014), which used two checklists to analyze the quality of
research. The sample sizes in this review ranged from three to 129. Two studies were conducted
in the United States and the remaining studies were conducted in Israel, Gaza, Belgium, Canada,
Japan, and the Netherlands. Including studies from various countries improves the ability to
apply this information across cultures, supporting cultural sensitivity.
The primary intervention examined in this body of literature was biofeedback, but
supplemental treatments including breathing retraining, mind-body skills sessions, clinical videoteleconferences, and a rehabilitation program were also studied (Swanson et al., 2009; Staples et
al., 2011; Tan et al., 2013; & Climov et al., 2014). The majority of studies measuring
biofeedback, measured HRV (Nahshoni et al., 2004; Swanson et al., 2009; Climov et al., 2014;
Zwan et al., 2015). Swanson et al. (2009) examined HRV biofeedback with respiration training.
Two studies included biofeedback that measured temperature and cerebral blood flow with the
heart rate (Staples et al., 2011; Kotozaki et al., 2014). Three studies out of the seven that used
biofeedback also used breathing retraining as an intervention (Swanson et al., 2009; Staples et
al., 2011; Tan et al., 2013). Patient outcomes examined in relation to the use of biofeedback and
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other alternative treatments were classified according to physical symptoms, psychological
symptoms, or both.
Despite the diversity among this literature, each of these studies reported evidence
indicating that biofeedback was a useful intervention for the physical symptoms of depression. In
addition, supplemental or holistic interventions were useful interventions for the psychological
symptoms of depression. Research showed that biofeedback alone does not have enough
supporting evidence to be considered as a solitary treatment option for patients with depression.
Yet, research did show that biofeedback that is paired with another type of intervention, such as
mind-body skills sessions, guided imagery, or meditation, may meet both the psychological and
physical needs experienced with depression.

Depression
Research findings showed significant changes in physical and/or psychological
depressive symptoms in five out of the eight studies retrieved in this review. The dependent
variables that dealt with depression and its symptoms were observed and measured as physical
symptoms, psychological symptoms, or both. Much like the purposes of this group of studies, the
outcomes reflected what the researchers aimed to discover. Variables addressing physical
symptoms included HRV, exercise tolerance, systolic and diastolic blood pressures, salivary
cortisol levels, and cerebral blood flow (Nahshoni et al., 2004; Swanson et al., 2009; Climov et
al., 2014, Kotozaki et al., 2014). The psychological variables included quality of life; symptoms
associated with post-traumatic stress disorder (PTSD); depressive symptoms; hopelessness; pain
intensity and unpleasantness; sleep disturbance or quality; anxiety; type D personality, and
psychological well-being (Swanson et al., 2009; Staples et al., 2011; Tan et al., 2013; Climov et
al., 2014; Canadian Agency for Drugs and Technologies in Health, 2014; Kotozaki et al., 2014;
12

Zwan et al., 2015). Following data analysis, it was evident that none of the studies focused only
on depression, revealing a gap in the literature concerning evaluation of biofeedback specifically
for patients with depression. Instead, this body of literature mainly evaluated depression and its
symptoms in addition to other psychological symptoms.
After analyzing the literature, the negative psychological symptoms of depression were
relieved when biofeedback was combined with other holistic treatments. For example, Tan et al.
(2013) evaluated an innovative treatment for women veterans who suffer from chronic pain
and/or depression associated with trauma. The authors found that depression was significantly
improved after women veterans participated in six weeks of home use with a biofeedback device
called the Stress Eraser (SE) and weekly clinical video-teleconferences. Statistically significant
improvements were found in pain unpleasantness, pain interference, depressive symptoms,
PTSD symptoms, and sleep disturbance. Improvements appeared to be maintained at 6-week
follow-up. Frequency of SE use was significantly associated with decrease in distressed mood
and decreased anxiety, while SE points obtained was significantly associated with decrease in
distressed mood (Tan et al., 2013). Most importantly, these improvements persisted after a
follow-up analysis six weeks later.
Nahshoni et al. (2004) conducted a study to measure the cardiac autonomic imbalance in
patients with MDD, hypothesizing that the HRV measures of patients with MDD would be
higher than those of the heart transplant recipients (who have denervated hearts) but lower than
those of the healthy comparison subjects. The mean interbeat interval and mean pointwise
correlation dimension (PD2) values for both the MDD and heart transplant groups were similar
and significantly lower than the control group. There was no significant difference between the
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MDD group and the transplant group with HRV, but there was a significant difference between
those groups and the healthy participants. Both the MDD and transplant groups had significantly
less HRV than the control group (Nashoni, 2004).
Zwan et al. (2015) found that physical activity created more improvement over
biofeedback in stress, anxiety, depression, sleep quality, and psychological well-being.
Participants in this study were assigned to one of three groups that either did physical activity,
mindfulness meditation, or heart rate variability biofeedback for five weeks, and heart rate
variability biofeedback was the intervention that showed the least improvement in psychological
well-being (Zwan et al., 2015). Climov et al. (2014) combined HRV Biofeedback with a
supplemental rehabilitation program to increase the cardiac coherence level in coronary artery
disease (CAD) patients. There were no statistically significant differences between the control
group and the biofeedback group in the evolution of the systolic or diastolic blood pressure
values over the course of the study. Most patients in the biofeedback group were able to increase
their cardiac coherence percentage significantly. These results reveal that when only looking at
the psychological elements of depression, biofeedback should be paired with another holistic
intervention in order to experience significant improvement.

Therapeutic Interventions
Among the eight articles examined in this literature review, four articles addressed
quality of life and psychological symptoms. Nahshoni et al. (2004) sought to investigate the
physical effects of biofeedback and three articles sought to accomplish both of the
aforementioned purposes (Swanson et al., 2009; Climov et al., 2014; Kotozaki et al., 2014). The
greatest number of independent variables being studied at once came to a total of eleven
interventions (Staples et al., 2011), which negatively impacted the ability to clearly identify its
14

effect, if any, on depression. Nahshoni et al. (2004) examined only one intervention, which
provided a clearer view of that intervention’s impact on patient outcomes. Studying such a large
number of interventions alongside biofeedback negatively impacts the ability to single out its
singular effect on depression.
Independent variables used in the research articles mostly included biofeedback as a
supplemental treatment alongside other interventions. Three studies out of the seven that used
biofeedback also used interventions of breathing retraining (Swanson et al., 2009; Staples et al.,
2011; Tan et al., 2013). These interventions often occur together due to the influence that
reduced respirations have on the parasympathetic system, which controls relaxation and
counteracts the overstimulation of the sympathetic system that can occur in depression (Swanson
et al., 2009).
Studies that used supplemental interventions alongside biofeedback showed the most well
rounded improvement of body and mind. For example, Staples et al. (2011) used supplemental
interventions to determine if the mind-body techniques could be effective for a broad range of
patients regarding age and cultural background. The authors also studied the effect of the
program on depression symptoms. After 10 sessions of the joint interventions, participants
reported decreased symptoms of PTSD and depression. A highly significant effect was shown
with time for PTSD, indicating that higher baseline scores resulted in greater improvements in
PTSD and the cluster symptoms following the intervention. A significant effect was found with
time on total depression scores and the subscales. Older children had more improvement in
avoidance scores from baseline to follow-up and girls’ scores remained significantly lower than
boys at follow-up. Pairwise controls showed that the overall PTSD score and cluster symptom
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scores significantly improved following the mind-body skills groups. Significant age-by-time
interaction was observed for the total depression score; negative self-esteem; interpersonal
problems; anhedonia; and negative self-esteem indicating that improvements in depression and
these subscales from baseline to follow-up were greater for older children. Overall depression
and subscale scores significantly improved post-intervention and were fully maintained at
follow-up for interpersonal problems, negative self-esteem, and ineffectiveness subscales.
In addition to revealing the value of using multiple types of therapeutic interventions, research
also proved that those who participated the most in these interventions, experienced the best
results.
Zwan et al. (2015) compared the effects of self-directed PA, MM, and HRV-BF on
perceived stress, anxiety, depression, sleep quality and psychological well-being in adults with
stress complaints. The significance of the changes experienced from the interventions depended
on how compliant the participants were during the five weeks of treatment. Participants who
trained for approximately 70% of the prescribed time indicated that greater compliance is
associated with larger effects of the interventions. The intervention group reported slightly better
sleep quality at pretest than the dropout group. Stress, anxiety, depression, sleep quality, and
psychological well-being all changed significantly in the expected direction over time. The PA
intervention yielded the largest effects. MM was the only intervention that improved sleep
quality (Zwan et al., 2015).

Biofeedback
Intervening with the use of biofeedback proved to be very beneficial for the physical
effects of depression, such as cardiovascular health, cortisol levels, and the respiratory system.
Among the seven studies that used biofeedback as in intervention, it was found that the most
16

popular type of biofeedback intervention measured physical data from the heart. More
specifically, biofeedback that measured HRV was used in 5 out of those 7 studies. The
remaining two studies included biofeedback that measured temperature, and cerebral blood flow
and heart rate (Staples et al., 2011; Kotozaki et al., 2014). Rather than causing significant
improvement with the psychological aspect of depression, biofeedback proved to significantly
improve the physical comorbidities that occur as a result of depression.
Patients with MDD had very similar heart rate variability to those who had a heart
transplant (Nahshoni et al., 2004). These results provide a clear example of how depression has a
negative effect on the autonomic nervous system, which in turn negatively affects the
cardiovascular system. Patients who had a heart transplant served as a comparison group of
denervated hearts to help prove the hypothesis that the cardiovascular imbalance of patients with
depression mirrors that of patients with heart diseases, which has great implications for how
interventions should be chosen for patients with depression (Nahshoni et al., 2004).
A decrease in HRV resulting from autonomic dysfunction has been known to increase
morbidity, mortality, and a poor prognosis for patients (Swanson et al., 2009). Swanson et al.
(2009) conducted research to examine the effects of a six week course of cardiorespiratory
biofeedback on exercise tolerance, HRV, and quality of life. Participants were selected based on
their medical status of heart failure and depression. There was a significant difference in the high
vs. low left ventricular ejection fraction (LVEF) in the control groups in relation to fatigue. HRV
biofeedback does not appear to be helpful for people with more severe disease, but was helpful
for people with milder disease. At the end of the study, they found that depression and quality of
life were not positively changed by the interventions. The treatment group had a higher increase
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in meters walked than did the control group, indicating an improvement for exercise tolerance
(Swanson et al., 2009). Even though there were no significant changes for the psychological
symptoms of depression in this study, the physical benefits are an aspect of care that should not
be ignored when treating these patients.
Kotozaki et al. (2014) investigated the anatomical correlates of biofeedback effects and the
psychological changes associated with those effects. Before and after four weeks of either
biofeedback sessions or no intervention, participants were measured for level of depression,
positive and negative effects, job stress, cortisol levels in saliva, and cerebral blood flow. The
biofeedback group displayed a significant decrease in depression scores, positive and negative
affect scores, and job stress. Salivary cortisol levels significantly decreased after the
biofeedback intervention, while regional gray matter variation (cerebral blood flow) increased
(Kotozaki et al., 2014). These positive results showed that biofeedback was affective as an
intervention in the face of daily hassles. Biofeedback was determined to be beneficial for two
reasons. First, participants were learning how to use emotional self-control in their daily life,
which in turn gave them more confidence to overcome stress from their jobs. Secondly,
biofeedback enhanced the parasympathetic activity which led to the positive physical changes in
heart rate, cortisol levels, and cerebral blood flow (Kotozaki et al., 2014).
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DISCUSSION
The literature reviewed demonstrated a consistent pattern of physical benefits from the
use of biofeedback, and psychological benefits from alternative interventions. Long-term
physical consequences of depression were relieved; however, this evidence has not been
addressed through current treatment guidelines. Biofeedback therapy, when paired with an
intervention that focuses on psychological symptoms, may result in significant health benefits for
patients with long term depression, such as, MDD, after finding benefits in the studies conducted
by Nahshoni et al. (2004) and Zwan et al. (2015).
The physical manifestations of depression reported by Karavidas et al. (2007), which
included decreased HRV and increased respiratory rate, were supported by this research
(Nahshoni et al., 2004; Swanson et al., 2009; Staples et al., 2011; Climov et al., 2014; Zwan et
al., 2015). Each of these five studies measured HRV and respiratory rate in an effort to correct
the negative impact of depression on physiological function. These studies support the findings
reported by Karavidas et al. (2007) concerning how depression affects HRV and respiratory rate.
This evidence further supports the use of biofeedback as a therapeutic intervention to address
those physical effects.
Including biofeedback, specifically cardiovascular related biofeedback, into the treatment
regimen for patients with depression has the ability to help decrease the effect that comorbid
cardiac diseases may have on the body (Nahshoni et al., 2004). Reducing the effect of
cardiovascular comorbidities will also reduce the amount of money that these patients are
spending on health care, and increase their time and ability to work. A dual treatment approach
for depression can provide the holistic treatment that these patients have been lacking. With
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guidelines that only include interventions like pharmacological treatment, cognitive behavioral
therapy, and group therapy sessions, biofeedback provides the physical support that these
patients need.
Cognitive behavioral therapy was not included in any of the studies examined for this
literature review, but structured group therapies were examined alongside biofeedback.
Pharmacotherapy was also used by some of the participants in the study conducted by Nahshoni
et al. (2004), but was not a variable that they chose to control, and therefore cannot be assessed
as being used in conjunction with biofeedback. Structured group therapies were the only type of
current guideline intervention that appeared in this literature (Staples et al., 2011; Tan et al.,
2013; Climov et al., 2014). Staples et al. (2011) and Tan et al. (2013) found significant
improvement for depression; however, Climov et al. (2014) did not find significant
improvements. None of the studies examined the use of neurofeedback to measure electrical
impulses from the nervous system. Kotozaki et al. (2014) studied cerebral blood flow and heart
rate with biofeedback and found significant changes in the blood flow to certain regions of the
brain following biofeedback therapy.
As a result of neurofeedback and CBT not being included as interventions in these eight
studies, it shows a lack of knowledge concerning neurofeedback and CBT alongside
biofeedback. Which in turn, leaves a large gap in the knowledge about how those interventions
could benefit a patient when paired together. Because of the research done by Cheon et al.
(2016) and NACBT (2016), who found that neurofeedback and CBT show positive results as
treatment for depression, it is necessary that future studies search for ways to enhance these
interventions with the addition of biofeedback.
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Empowering patients with information about how depression can affect the body, and
teaching them how to control those affects through biofeedback, is a positive step in the direction
towards improving their quality of life. After looking at the eight studies and finding that
physical symptoms also play a large role in depression, it would be a beneficial next step to
research how adding that type of intervention could be financially beneficial. The studies
examined in this review did not focus on financial benefits that patients could experience while
participating in the interventions, yet some of the improvements that the patients experienced
could be found to benefit them financially. For example, in the study conducted by Swanson et
al. (2009), they found that participants in the biofeedback group experienced significant
improvement in distance walked. Such improvements in activity tolerance could increase a
patient’s ability to attend work, decreasing the amount of times they take sick days, which was a
problem that Greenburg et al. (2015) found in patients with depression. In light of these
conclusions, it is still necessary to perform studies to support the idea that there could be
financial benefits to biofeedback.
However, it is necessary to stress that meeting the immediate psychological needs of a
patient with depression is very important before biofeedback can be beneficial. A patient
experiencing suicidal thoughts will most likely not change their mind by attending a biofeedback
therapy session. Biofeedback should be used as a tool of empowerment and physical health for
patients who are also receiving psychological support. Treating depression through the mind and
body will greatly enhance the quality of life of those living with depression in a holistic way.
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LIMITATIONS
This literature review was limited by the lack of relevant articles dealing with
biofeedback as a treatment for patients solely dealing with the diagnosis of MDD. Research
studies that examined depression as a secondary or additional variable decreased this reviews
ability to make conclusions about biofeedback’s effect on depression alone. There were also no
studies that sought to examine biofeedback as a supplemental treatment with pharmacotherapy,
cognitive behavioral therapy, or electroconvulsive therapy. The absence of existent studies on
these subjects reveals the need for future research to explore biofeedback paired with the
treatments that are current guidelines for depression management.
Limitations that impacted the effectiveness of the included studies were: small sample
sizes, limited generalizability, participant drop out, incomplete data, limitations of study design,
uncontrolled variables, unconsidered chronic illnesses, follow-up information that was absent or
not long enough, and lastly, a lack of finances. Each study experienced at least one of these
limitations. The most common limitation experienced throughout the studies was a small sample
size. Small sample sizes limited the ability for conclusions to be made concerning the majority
of the population, so biofeedback cannot be said to cause results in every patient with depression.
Including studies from multiple countries in this review was a strength that gave
credibility to the possible impact of depression in different cultures. Yet, the review was limited
by the studies that used participants of one gender (Tan et al., 2013; Climov et al., 2014;
Kotozaki et al., 2014) or had one gender outnumber the other (Staples et al., 2011).
These limitations should be addressed when conducting future research to enhance the
credibility and relevance of the study for all people struggling with depression.
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RECOMMENDATIONS
Biofeedback therapy for patients with depression or depressive symptoms has proven to
be beneficial on the autonomic nervous system, which in turn improves the regulation of the
cardiovascular system. These benefits, however, were enhanced when paired with an
intervention that met the psychological needs of participants. Although, in order to apply these
results to patients who only have MDD, and not a comorbid psychological or physical ailment,
future research needs to be conducted excluding participants with comorbid ailments.
Future research also needs to include studies that examine the effects of biofeedback
when paired with current guidelines for the treatment of depression. There are currently no
studies that focus on biofeedback paired with cognitive behavioral therapy, pharmacotherapy,
electroconvulsive therapy, or others that are considered for treatment. In order for biofeedback
to be considered as a viable option for supplemental treatment with depression, these types of
studies need to be conducted.
It would also be particularly beneficial to incorporate the study of biofeedback on
depression into a longitudinal study. Knowing the effects of this type of therapy over months to
years would greatly increase how it is used in patients with MDD, since they suffer with
depression chronically.
Before recommending the use of biofeedback to patients with depression, it is paramount
that health care providers analyze the patient’s ability and self-motivation to follow through with
the intervention. As previously stated, unaddressed suicidal or homicidal thoughts need to be
managed with another treatment before using biofeedback therapy in their regimen.
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Biofeedback, however, should be considered for patients seeking an alternative therapy that
addresses physical needs.
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CONCLUSIONS
Research tells us that when it comes to treating depression, there needs to be a
multifaceted approach. This literature review found that the type of biofeedback being used
most frequently in patients with depression, or depression symptoms, was HRV biofeedback.
The cardiovascular system was the system that was being affected the most because of
depression’s effect on the autonomic nervous system. As a result of these findings, it is
important to treat depression for both its psychological effects as well as its physical effects.
Studies do not currently have enough evidence to include biofeedback into the treatment
guidelines for depression, but with future research, it has the potential to prove to be an aid in the
physical needs of patients dealing with long term depression. Nursing practice should continue
to look into the efficacy of biofeedback as an alternative treatment for their patients. When
seeking to holistically care for those suffering with depression, nurses need to consider
treatments that address more than just the negative psychological effects. Biofeedback therapy
should be an intervention that patients are educated about, because it is the job of health care
providers to empower patients with therapeutic choices available to help them cope and improve
their quality of life. After all, patients deserve the very best that research and holistic treatments
have to offer them, so that they can live their best life.
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APPENDIX A:
Figure 1
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Relevant research articles that were identified after searching the databases of: CINAHL
Plus with Full Text, Cochrane Central Register of Controlled Trials, Cochrane Database of
Systematic Reviews, MEDLINE, PsycARTICLES, and PsycINFO
(n = 170)

Included limiter of:
English language
(n = 85)

Research articles underwent a
review of their titles to meet
inclusion criteria:
(n=27)

Research articles underwent an
analysis of their abstracts for
inclusion criteria and relevance to the
study:
(n= 11)

Research articles were
critiqued for reliability of
evidence and necessary
information:
(n = 8)
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APPENDIX B:
Table of Evidence
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Author(s),
Year, Location
Nahshoni,
Aravot,
Aizenberg,
Sigler,
Zalsman,
Strasberg,
Imbar, Adler,
& Weizman
2004
Petach Tikva,
Israel

Study Design
and Purpose
Crosssectional
design
The purpose
of this study
was to
measure the
cardiac
autonomic
imbalance in
participants
with
depression,
participants
with postheart
transplants,
and healthy
participants

Sample Size
30 subjects
n = 10
inpatients
who met the
DSM-IV
criteria for
Major
Depressive
Disorder
(MDD)

Research
Variables
ECG readings
of HRV were
taken for all
three groups of
participants.
The dependent
variable in this
study was the
frequency of
HRV

Study Design
and Purpose
2 (treatment
vs. control) x

n = 10 nonhospitalized
patients who
had and
orthotopic
heart
transplant

Sample Size
29 heart
failure

ECG recordings
were gathered
during spontaneous
breathing for all
subjects, patients
with Major
Depression, posttransplantation
patients, and the
healthy patients.
The time-domain
measured the mean
of the normal RR
intervals (in msec)
and the standard
deviation of the
entire recording
(SDRR, in msec)
were obtained for
each data point

n = 10
physically
healthy
volunteers
Author(s),
Year, Location
Swanson,
Gevirtz,

Data Collection

Research
Variables
Heart failure
patients
29

Key Findings and Limitations
The mean interbeat interval and mean
pointwise correlation dimension (PD2)
values for both the MDD and heart
transplant groups were similar and
significantly lower than the control
group.
There was no significant difference
between the MDD group and the
transplant group with HRV, but there
was a significant difference between
those groups and the healthy
participants. Both the MDD and
transplant groups had significantly less
HRV than the control group.
The study was non-experimental. The
sample size was small. The effect of the
immunosuppressant drugs on the cardiac
autonomic nervous system of the
patients with post-transplantation is
unknown. The SSRIs taken by the
patients with depression may have
affected their HRV

Data Collection

Key Findings and Limitations

Pretreatment
Measures:

There were no significant baseline
differences between the treatment and

Brown, Spira,
Guarneri, &
Stoletniy
2009
Loma Linda,
CA

3 (pre, post,
and followup)
randomized,
single-blind,
controlled,
factorial
design with
repeated
measures.
The purpose
of this study
was to
discover if a 6
week course
of
cardiorespirat
ory
biofeedback
would
increase
exercise
tolerance and
HRV, and
improve
quality of life.

patients
Group 1:
(n = 15)
Group 2:
(n = 14)
Participants
were
randomly
assigned to
either the
treatment
group
(Group I) or
the attention
placebo
control group
(Group II)

underwent 6
weeks of heart
rate variability
(HRV)
biofeedback,
and breathing
retraining.

Demograhics
Health
Questionnaire

Outcome Measures:
6 Minute Walk
Test; Borg Scale;
Physiological
Monitoring and
The study
Instrumentation
evaluated the
(HRV measures,
effect of
Electrocardiograph,
biofeedback on Pneumograph
exercise
magnetic strain
tolerance, HRV, gauge); Minnesota
and quality of
Living with Heart
life.
Failure
Questionnaire;
Positive and
Negative Affect
Scale (PANAS),
and Center for
Epidemiological
Studies-Depression
Scale.
Other Measures:
Credibility/
Expectancy
Questionnaire;
Stress Management
30

control groups on demographic or
clinical variables. Dyspnea approached
significance between the two groups.
There was a significant difference in the
high vs. low left ventricular ejection
fraction (LVEF) in the control groups in
the area of fatigue.
The treatment group had a higher
increase in meters walked than did the
control group. The difference was higher
for participants in high LVEF category.
An important finding was that HRV
biofeedback does not appear to be
helpful for people with more severe
disease. It help people with milder
disease.
No relationship was found with
depression, mood, amount of time
practiced, level of dyspnea or fatigue,
perception of credibility of treatment.
33% of the treatment group displayed a
clinically significant increase in distance
walked between baseline and follow-up
measures. While, only 12.5% of the
control group demonstrated clinical
significance in distance walked.

and Exercise
Practices
Questionnaire;
Medication Record;
Practice Logs;
Daily Stress
Management and
Exercise Record,
and Vital Signs.

Author(s),
Year, Location
Staples, Atti,
& Gordon

Study Design
and Purpose
Randomized
Controlled
Trial

2011
Gaza

Sample Size
129 children
and
adolescents
with PostTraumatic
Stress
Disorder
(PTSD)

This study
sought to
evaluate
mind-body
skills groups
that were led
There were 8by 37 trained
10 children in
health and
each group.
mental health
professionals
and educators.
The purpose

Research
Variables
Mind-body
skills sessions
included deep
breathing;
drawing,
temperature
biofeedback and
autogenic
training, guided
imagery, selfawareness body
scan meditation,
fast deep
breathing
followed by
free movement
to music, eating
31

Data Collection
The Child PTSD
Symptom Scale
(CPSS) was used to
screen the children
for PTSD
symptoms.
The Children’s
Depression
Inventory measured
behavioral,
cognitive, and
affective symptoms
with five subscales:
total depression
score, negative
mood, interpersonal

This study was limited financially and
was unable to examine post or follow-up
LVEF values. Due to attrition, the
ability to evaluate participants who had
a greater degree of negative mood,
depressive symptoms, and reduced
HRV. The small sample size limits the
generalizability of the results. The study
was also limited by time. A longer
follow-up period was not possible and
later improvements were not measured.
Key Findings and Limitations
There was a weak, but statistically
significant correlation between baseline
PTSD scores and exposure to military
violence. A highly significant effect was
shown with time for PTSD, reexperiencing, arousal, and avoidance,
indicating that higher baseline scores
resulted in greater improvements in
PTSD and the cluster symptoms
following the intervention.
A significant effect was found with time
on total depression scores and the
subscales.
Both age-by-time and sex-by-time
interaction effects were significant.

of this study
was to
determine if
the mindbody
techniques
developed by
the Center for
Mind-Body
Medicine
could be
effective in a
study with a
broader range
of age and
different
cultural
background.
They also
wanted to see
the effect of
the program
on depression
symptoms, as
well as in an
area with
ongoing
conflict,
threats, and
stress.

meditation,
genograms, and
a dialogue with
a symptom.
PTSD,
depression, and
hopelessness
were all
evaluated after
the completion
of the mindbody sessions.
10 sessions
were held for
two hours twice
a week. Each
session
consisted of
meditation,
guided imagery,
breathing
techniques,
autogenic
training,
biofeedback,
genograms, and
self-expression
through words,
drawings, and
movement.
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problems,
ineffectiveness,
anhedonia, and
negative selfesteem.
The Hopelessness
Scale for Children
(HSC) measured
whether the sense
of hope after the
mind-body skills
groups.

Older children had more improvement in
avoidance scores from baseline to
follow-up and girls’ scores remained
significantly lower than boys at followup.

There was a significant effect of the
baseline scores on the total depression
score; negative mood; ineffectiveness;
anhedonia; and negative self-esteem,
indicating that higher baseline scores
resulted in greater improvements in
depression and all five subscales
following the groups.

Trauma exposure
was measured using
a checklist created
For the avoidance cluster symptom, age
by the clinical
effect was significant, implying that
director.
older children had more improvement in
avoidance scores.
Data from children
not meeting the
Pairwise controls showed that the
PTSD criteria were overall PTSD score and cluster symptom
not fully analyzed
scores significantly improved following
except to compare
the mind-body skills groups. Yet, the
initial differences in data from the children not meeting the
exposure levels to
PTSD criteria were not analyzed fully.
military trauma
Instead, it was used to compare the
with children
differences in exposure levels to military
meeting PTSD
trauma with the children meeting PTSD
criteria and to
criteria and analyze the effect of the

analyze the effect
of the initial PTSD
status in the linear
mixed models for
the outcome
measure.

initial PTSD status in the linear mixed
models for the outcome measure.
Significant age-by-time interaction was
observed for the total depression score;
negative self-esteem; interpersonal
problems; anhedonia; and negative selfesteem indicating that improvements in
depression and these subscales from
baseline to follow-up were greater for
older children.
Overall depression and subscale scores
significantly improved post-intervention
and were fully maintained for
interpersonal problems, negative selfesteem, and ineffectiveness subscales.
Improvement was partially maintained
for total depression score and subscales
of anhedonia and negative mood.

Author(s),
Year, Location

Study Design
and Purpose

Sample Size

Research
Variables

Data Collection
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A limitation of this study was that large
amounts of data were missing at followup. Significantly more girls followed up
because many of boys had begun
working and were unavailable.
Key Findings and Limitations

Tan, Teo,
Srivastava,
Smith, Smith,
Williams, &
Jensen
2013
Houston,
Texas

Quasiexperimental
design
This study
was designed
to evaluate the
possibility of
an innovative
treatment for
women
veterans
living in rural
areas who
suffer from
chronic pain
and/or
depression
associated
with trauma.
This study
chose to
compare
pretreatment
and
posttreatment
self-reported
measures to
assess any
changes that

34 female
veterans
Participants
underwent 6
weeks of
home practice
with the
Stress Eraser
(SE)
biofeedback
device and
kept a log that
recorded their
daily practice.
Training was
paired with
weekly
clinical videoteleconference
(CVT)
support
sessions.

The
independent
variables were
the SE device
for biofeedback,
and the CVT
support
sessions.

Cognitive
Impairment was
measured using the
Short OrientationMemoryConcentration Test
of Cognitive
Impairment.

The dependent
variables
included PTSD
symptoms,
depression
symptoms, pain
intensity and
unpleasantness
and sleep
disturbance.

Psychopathology
and/or substance
abuse were
measured with the
Mini-International
Neuropsychiatric
Interview.
PTSD symptoms
were measured
using the PTSD
Check List –
Civilian version.
Depressive
symptoms were
measured using the
Center for
Epidemiological
Studies Depression
Scale.

Follow-up
assessments
were
completed 6
weeks after
the final
34

Pain intensity did not significantly
decrease from pretreatment to
posttreatment, or pretreatment to followup. However, statistically significant
improvements were found in pain
unpleasantness, pain interference,
depressive symptoms, PTSD symptoms,
and sleep disturbance. Improvements
appeared to be maintained at 6-week
follow-up.
Frequency of SE use was significantly
associated with decrease in distressed
mood and decreased anxiety, while SE
points obtained was significantly
associated with decrease in distressed
mood.
The sample of women veterans studied
presented with multiple symptoms and
issues, making them a challenging group
to investigate.
Given the small sample size of the
current preliminary study, the power to
detect significant treatment effects may
have been reduced.
This study did not seek to assess factors
that can impact delivery and success of
the treatment.

could be
associated
with the
intervention.

session to
detect
improvements
over a short
period of
time.

Pain intensity and
unpleasantness
were measured
using adapted
versions of
measures of
sensory intensity
and affective
magnitude.

Focus groups
were
conducted to
determine the
acceptability
of the SE
device and the
CVT sessions.

Author(s),
Year, Location
Climov, Lysy,
Berteau,
Dutrannois,
Dereppe,

Study Design
and Purpose
randomized
controlled
study

Sample Size
N = 24
n = 13
(experimental

Pain interference
was measured using
the Pain
Interference Short
Form of the PatientReported Outcomes
Measurement
Information
System.

Research
Variables
The
independent
variables were
the cardiac
35

Sleep disturbance
was assessed using
the Medical
Outcomes Study
Sleep measure.
Data Collection

Key Findings and Limitations

All measurements
were obtained at the
start of the
programs for both

Blood Pressure:
There were no statistically significant
differences between the control group
and the biofeedback group in the

Brohet, &
Melin
2014
Brussels,
Belgium

The purpose
of this study
was to
investigate the
feasibility of
applying heart
rate
variability
(HRV)
biofeedback
in order to
increase the
cardiac
coherence
level in
coronary
artery disease
(CAD)
patients
participating
in a cardiac
rehabilitation
program.

)
n = 11
(control)
The
experimental
group
participated in
10 sessions of
cardiac
coherence
biofeedback
training in
addition to the
rehabilitation
program.
The control
group only
participated in
the usual
cardiac
rehabilitation
program.

coherence
biofeedback
training and the
rehabilitation
program.
The dependent
variables
consisted of
physiological
variables and
psychosocial
variables. The
physiological
variables were:
systolic and
diastolic blood
pressures, and
HRV. The
psychosocial
variables were:
anxiety,
depression, and
type D
personality.

groups and at the
evolution of the systolic or diastolic
end of the programs blood pressure values over the course of
6 weeks later.
the study.
Blood pressures
were taken with a
mercury sphygmomanometer.
HRV was analyzed
with a 24-hour
ECG Holter
monitor.
Anxiety and
depression levels
were assessed using
the Hospital
Anxiety and
Depression Scale
(HADS)
questionnaire.
Emotional and
social problems
associated with
type D personality
were assessed a
questionnaire.
Cardiac coherence
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HRV:
The biofeedback group’s standard
deviation of the NN intervals (SDNN)
increased in 5 patients, decreased in 4
patients and remained stable in 1 patient.
This represents a 7% increase in HRV.
The control group’s SDNN increased in
4 patients, decreased in 3 patients and
remained unchanged in 1 patient. This
represents a relative increase of 5.7%.
Psychological Parameters:
Score levels for depression and anxiety
decreased slightly in the biofeedback
group compared to the control group,
but the difference was not statistically
significant.
Cardiac Coherence:
Most patients in the biofeedback group
were able to increase their cardiac
coherence percentage significantly.
All of the participants were male.
The sample size was rather small.
Lack of participation in the home
practice. Biofeedback sessions were

Author(s),
Year, Location
Canadian
Agency for
Drugs and
Technologies
in Health
2014
Canada

Study Design Sample Size
and Purpose
This study is a n = 3 reports
systematic
total
review.
n = 1 (PTSD
The purpose
study)
of this study
was to update n = 2
a previous
(Depression
summary of
studies)
the evidence
on the clinical
effectiveness
and safety of
neurofeedbac
k and
biofeedback
in the
treatment of
post-traumatic
stress disorder
(PTSD),
generalized
anxiety
disorder
(GAD), or

Research
Variables
Variables of
interest
included
neurofeedback
and
biofeedback.

was calculated
using the Freeze
Framer system.
Data Collection

sometimes scheduled at different
moments of the morning. Data were
missing.
Key Findings and Limitations

The quality of the
included systematic
review was
assessed using
AMSTAR. The
quality of the
included RCT was
assessed using
Downs and Black
checklist.

No studies on the clinical evidence
regarding the benefits and harms of
neurofeedback for PTSD, GAD, or
depression were identified.

Numerical scores
were not calculated.
The strengths and
limitations of
individual studies
are summarized and
presented.
Three studies were
included in the
review: One was a
systematic review,
one was an RCT,
and one was a

37

No significant changes in PTSD
symptoms were reported after
biofeedback.
In the non-RCT, biofeedback had a
beneficial effect on depressive
symptoms in senior patients.
No evidence-based guideline were
identified.
Only 3 studies were assessed.
There were no studies identified for
patients with GAD.
Due to the limited number of
biofeedback studies identified (n = 3)
and the poor quality of the clinical trials,
it is difficult to draw definitive
conclusions regarding the clinical
effectiveness and safety of biofeedback

depression.

Author(s),
Year, Location
Kotozaki,
Takeuchi,
Sekiguchi,
Yamamoto,
Shinada,
Araki,
Takahashi,
Taki, Ogino,
Kiguchi,
Kawashima
2014
Sendai, Japan

Study Design
and Purpose
randomized,
double-blind,
controlled,
crossover
trial.

Sample Size

The aim of
this study was
to investigate
the
anatomical
correlates of
biofeedback
effects and the
psychological
changes
associated
with those
effects.

n= 15
(Control
Group)

30
n= 15
(Intervention
Group)

Participants
in the
intervention
group
underwent 4
weeks of
biofeedback
intervention
sessions,
while the
control group
went through
normal
everyday life

Research
Variables
The
independent
variable was the
biofeedback
therapy that
measured
cerebral blood
flow and heart
rate.
The dependent
variables were
psychological
changes,
salivary cortisol
levels, and gray
matter structure
changes.
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cohort study.

on PTSD and depression.

Data Collection

Key Findings and Limitations

Psychological
effects were
measured using the
Center for
Epidemiologic
Studies Depression
Scale (CES-D), the
General Health
Questionnaire 30,
the Positive and
Negative Schedule
(PANAS), and the
Brief Job Stress
Questionnaire
(BJSQ).

Psychological Measures:
The biofeedback group exhibited a
significant decrease in the
postintervention CES-D, PANAS-NA,
and BJSQ tension, depression, and
stressors of working environment
scores; a significant increase in the
BSJQ aptitude for the job scores was
also exhibited.

Saliva samples
were collected for
analysis of cortisol
levels.
MRI datum were
collected using the
3T Intera Achieva
MRI scanner and

The biofeedback group showed a
significant increase in the rGMV of the
right lateral orbitofrontal cortex (OFC)
and around the left subgenual anterior
cingulate cortex (sgACC).

The biofeedback group exhibited a
significant decrease in salivary cortisol
levels, indicating a greater reduction in
stress in this group compared to the
control group.

All of the participants were men.
Middle-aged subjects may have been

Author(s),
Year, Location
Zwan, Vente,
Huizink,
Bögels, &
Bruin
2015
Amsterdam,
Netherlands

Study Design
and Purpose
randomized
controlled
trial
The purpose
of this study
was to
compare the
effects of selfdirected PA,
MM, and
HRV-BF on
perceived
stress,
anxiety,
depression,
sleep quality
and
psychological
well-being in
adults with
stress
complaints.

without an
intervention
for 4 weeks.
Sample Size
75 adults
n = 23
(Physical
Activity
group)
n = 27
(Mindfulness
Meditation
group)
n = 25 (Heart
rate
variability
biofeedback
group)
A total of 19
participants
dropped out
after the pretest, but
before the
intervention
started.

Research
Variables
The
independent
variables were
physical
activity,
mindfulness
meditation, and
heart rate
variability
biofeedback.
The dependent
variables were
stress, anxiety,
depression,
sleep quality,
and
psychological
well-being.
Physical
activity (PA),
mindfulness
meditation
(MM), and
HRV
39

the voxel-based
morphometry
(VBM).
Data Collection

chronically exposed to stress and may
have developed damage to some brain
areas as a result.
Key Findings and Limitations

Measurements of
depression, anxiety,
and stress were
conducted using the
Dutch version of
the Depression
Anxiety Stress
Scales (DASS).

The intervention group reported slightly
better sleep quality at pretest than the
dropout group. Psychological well-being
at pre-test was lower in participants with
missing data compared to those with
data.

Stress, anxiety, depression, sleep
quality, and psychological well-being all
Sleep quality was
changed significantly in the expected
measured using the direction over time. The PA
Dutch version of
intervention yielded the largest effects.
the Pittsburgh Sleep MM was the only intervention that
Quality Index
improved sleep quality. HRV-BF did not
(PSQI).
reduce depressive symptoms in contrast
to the other interventions. Psychological
Psychological well- well-being improved less in the HRVbeing was
BF group compared to other groups.
measured using the
Dutch version of
Participants who trained for
the Scales of
approximately 70% of the prescribed
Psychological
time showed larger regression
Well-being (SPW). coefficients compared to the complete
sample, indicating that greater
compliance is associated with larger
effects of the interventions.

biofeedback
(HRV-BF) were
examined in
relation to
stress.
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Long term effects were not assessed in
this study. Missing data from
participants makes it possible that the
intervention effect may have been
slightly overestimated. Self-report
measures are sensitive to method
variance or social desirability effects.
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